SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR
NEW YORK, April 11, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
紐約， 2023年4月11日 /PRNewswire/ — 投資者權益律師事務所Halper Sadeh LLC正在調查以下公司是否可能違反聯邦證券法和/或違反與股東有關的信託義務：
Ranger Oil Corporation (NASDAQ: ROCC)'s sale to Baytex Energy Corp. Under the terms of the agreement, Ranger shareholders will receive 7.49 Baytex shares plus $13.31 in cash, for each Ranger common share. If you are a Ranger shareholder, click here to learn more about your rights and options.
蘭傑石油公司（納斯達克股票代碼：ROCC）的 出售給Baytex Energy Corp. 根據協議條款，Ranger股東將獲得7.49股Baytex股票以及 13.31 美元 每股 Ranger 普通股均以現金支付。 如果你是Ranger的股東 點擊此處詳細瞭解您的權利和選項。
Kimball International, Inc. (NASDAQ: KBAL)'s sale to HNI Corporation for $9.00 in cash and 0.1301 shares of HNI common stock for each share of Kimball common stock. If you are a Kimball shareholder, click here to learn more about your rights and options.
Kimball Inc.（納斯達克股票代碼：KBAL）的 出售給 HNI 公司 9.00 美元 現金，每股Kimball普通股可獲得0.1301股HNI普通股。 如果你是 Kimball 的股東 點擊此處詳細瞭解您的權利和選項。
Adaptimmune Therapeutics plc (NASDAQ: ADAP)'s merger with TCR2 Therapeutics Inc. Under the terms of the agreement, TCR2 stockholders will receive 1.5117 Adaptimmune ADS for each TCR2 share. Following the closing of the transaction, Adaptimmune shareholders will own approximately 75% of the combined company. If you are a Adaptimmune shareholder, click here to learn more about your rights and options.
Adaptimmune Therapeutics plc（納斯達克股票代碼：AD 與TCR2 Therapeutics Inc.合併。根據協議條款，TCR2股東每持有TCR2股票將獲得1.5117 Adaptimmune ADS。交易完成後，Adaptimmune股東將擁有合併後公司約75％的股份。 如果你是 Adaptimmune 的股東， 點擊此處詳細瞭解您的權利和選項。
TCR2 Therapeutics Inc. (NASDAQ: TCRR)'s sale to Adaptimmune Therapeutics plc for 1.5117 Adaptimmune ADS for each TCR2 share is fair to TCR2 shareholders. Following the closing of the transaction, TCR2 stockholders will own approximately 25% of the combined company. If you are a TCR2 shareholder, click here to learn more about your rights and options.
TCR2 Therapeutics Inc.（納斯達克股票代碼：TCRR）的 以每股TCR2股1.5117 Adaptimmune ADS的價格出售給Adaptimmune Therapeutics plc對TCR2股東來說是公平的。交易完成後，TCR2股東將擁有合併後公司約25％的股份。 如果你是 TCR2 的股東， 點擊此處詳細瞭解您的權利和選項。
Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Halper Sadeh LLC可能會代表股東尋求增加對價，尋求有關擬議交易的更多披露和信息，或代表股東尋求其他救濟和福利。
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].
鼓勵股東聯繫公司 免費的 討論他們的合法權利和選擇。請致電 丹尼爾·薩德 要麼 扎卡里·哈爾珀 致電 (212) 763-0060 或發送電子郵件至 [電子郵件保護] 要麼 [電子郵件保護]。
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Halper Sadeh LLC代表世界各地成爲證券欺詐和公司不當行爲的受害者的投資者。我們的律師在實施公司改革和代表受騙投資者追回數百萬美元方面發揮了重要作用。
Attorney Advertising. Prior results do not guarantee a similar outcome.
律師廣告。先前的結果並不能保證類似的結果。
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
聯繫信息：
Halper Sadeh LLC
丹尼爾·薩德，Esq
Zachary Halper，Esq.
(212) 763-0060
[電子郵件保護]
[電子郵件保護]
SOURCE Halper Sadeh LLP
來源 Halper Sadeh LLP